Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Head & Neck 2Gastrointestinal 2Endocrine 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Lymphoid 1

Conditions

Thyroid Carcinoma, Anaplastic 2Thyroid Neoplasms 1Neoplasms 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
efatutazone × Head & Neck × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT00603941 2020-09-16

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Daiichi Sankyo

Phase 1/2 Terminated
19 enrolled 13 charts
EndocrineHead & Neck

Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡